Acceleron Pharma Inc. (NASDAQ:XLRN)‘s stock had its “hold” rating reiterated by stock analysts at Oppenheimer Holdings, Inc. in a research note issued to investors on Tuesday.

Several other analysts have also issued reports on the company. Credit Suisse Group set a $51.00 price objective on Acceleron Pharma and gave the stock a “buy” rating in a report on Tuesday, November 14th. HC Wainwright increased their price objective on Acceleron Pharma from $57.00 to $62.00 and gave the stock a “buy” rating in a report on Tuesday, November 7th. Royal Bank Of Canada reiterated a “hold” rating on shares of Acceleron Pharma in a report on Thursday, November 2nd. ValuEngine lowered Acceleron Pharma from a “hold” rating to a “sell” rating in a report on Friday, October 6th. Finally, Barclays PLC increased their price objective on Acceleron Pharma from $42.00 to $50.00 and gave the stock an “overweight” rating in a report on Wednesday, September 20th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. Acceleron Pharma presently has an average rating of “Buy” and a consensus target price of $44.88.

Shares of Acceleron Pharma (NASDAQ XLRN) traded up $1.74 during trading hours on Tuesday, hitting $38.71. The company had a trading volume of 284,820 shares, compared to its average volume of 306,547. Acceleron Pharma has a twelve month low of $23.07 and a twelve month high of $40.35.

Acceleron Pharma (NASDAQ:XLRN) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.67) by $0.02. Acceleron Pharma had a negative return on equity of 40.70% and a negative net margin of 759.34%. The business had revenue of $3.00 million during the quarter, compared to analyst estimates of $3.52 million. During the same period last year, the company earned ($0.55) earnings per share. Acceleron Pharma’s quarterly revenue was up .0% compared to the same quarter last year. analysts predict that Acceleron Pharma will post -2.67 EPS for the current year.

TRADEMARK VIOLATION WARNING: This report was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/11/19/acceleron-pharma-inc-xlrn-receives-hold-rating-from-oppenheimer-holdings-inc.html.

In other Acceleron Pharma news, major shareholder Corp /De/ Celgene purchased 745,592 shares of the stock in a transaction dated Monday, September 25th. The shares were bought at an average cost of $37.00 per share, with a total value of $27,586,904.00. Following the completion of the transaction, the insider now owns 6,118,479 shares in the company, valued at approximately $226,383,723. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Christopher Rovaldi sold 14,000 shares of the firm’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $38.41, for a total value of $537,740.00. Following the completion of the sale, the senior vice president now directly owns 28,232 shares in the company, valued at $1,084,391.12. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 53,513 shares of company stock worth $2,055,485. 3.90% of the stock is currently owned by company insiders.

Several large investors have recently modified their holdings of the company. BlackRock Inc. grew its position in shares of Acceleron Pharma by 9.0% in the second quarter. BlackRock Inc. now owns 4,005,228 shares of the biopharmaceutical company’s stock valued at $121,719,000 after purchasing an additional 330,635 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Acceleron Pharma by 6.1% in the second quarter. Vanguard Group Inc. now owns 2,029,040 shares of the biopharmaceutical company’s stock valued at $61,663,000 after purchasing an additional 116,705 shares during the last quarter. Westfield Capital Management Co. LP grew its position in shares of Acceleron Pharma by 46.6% in the second quarter. Westfield Capital Management Co. LP now owns 1,682,359 shares of the biopharmaceutical company’s stock valued at $51,127,000 after purchasing an additional 534,440 shares during the last quarter. Perceptive Advisors LLC grew its position in shares of Acceleron Pharma by 127.2% in the third quarter. Perceptive Advisors LLC now owns 1,616,259 shares of the biopharmaceutical company’s stock valued at $60,319,000 after purchasing an additional 905,000 shares during the last quarter. Finally, Eagle Asset Management Inc. grew its position in shares of Acceleron Pharma by 6.6% in the second quarter. Eagle Asset Management Inc. now owns 1,256,642 shares of the biopharmaceutical company’s stock valued at $38,189,000 after purchasing an additional 77,683 shares during the last quarter. 76.99% of the stock is currently owned by institutional investors.

Acceleron Pharma Company Profile

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Analyst Recommendations for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.